South Korea prosecutors indict Novartis execs on drug sale rebate charges

HQ
Novartis

South Korean prosecutors indicted 6 executives from the local unit of Swiss-based Novartis ($NVS) for paying rebates to doctors in return for prescribing the company's drugs to patients in a sweep that also netted 15 doctors and 6 medical publishers.

The Korea Herald reports the executives included suspended Novartis Korea chief Moon Hak-sun in an allegedly illegal sales effort that saw the doctors at general hospitals receive KRW2.59 billion ($2.3 million) in payments in either cash or through arrangements with the medical publications via conference appearances and fees for articles.

South Korean health regulators and prosecutors have worked in tandem for years to halt domestic and foreign firms paying rebates on drug sales since passing a drug anti-rebate law in 2013.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

The latest case with Novartis launched by the Seoul Western District Prosecutors' Office was acknowledged by the local unit of the company, which issued a statement saying it does not "tolerate misconduct and we are already implementing a remediation plan in Korea based on the findings from our own investigation."

The case first surfaced in February of this year with investigators examining whether the company and its executives systematically encouraged the practices, a charge Novartis rejects.

Novartis has faced some hot water in relation to sales in Asia in the past year. In March the company agreed to pay $25 million to settle a Securities and Exchange Commission investigation into bribery allegations in China that included travel and other inducements to boost prescriptions of its drugs in the country.

- here's the story from The Korea Herald

Related Articles:
Novartis CEO eyes biosimilar plays in Asia that fit with Sandoz plans
Prosecutors raid Novartis South Korea in kickbacks probe
Novartis wraps up China bribery probe with $25M payment to SEC

Suggested Articles

The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.

Bristol-Myers Squibb’s takeover of Celgene hasn’t always gone smoothly, but now a once-left-for-dead centerpiece of that deal is ready to launch.

Investors sued Novo Nordisk in Denmark, claiming it misled the public about trouble plaguing its insulin franchise—and demanding $1.75B in damages.